WebOfPharma · Health-based cleaning limits

PDE, ADE and HBEL in Pharmaceutical Cleaning

A clear GMP guide to the three health-based terms, how they relate, how they differ, and how they become practical cleaning-validation controls.

PDE vs ADE vs HBEL Toxicology MACO limits Shared equipment

Quick answer: HBEL is the umbrella concept for a health-based exposure limit. PDE and ADE are commonly used expressions of that limit, usually reported as an acceptable daily exposure to a substance. In pharmaceutical cleaning, the approved PDE or ADE becomes a toxicological input for carryover limits, MACO calculations, equipment-sharing decisions, sampling criteria and routine verification. The terms describe health risk; they do not replace visual cleanliness, microbial controls, detergent limits or a validated cleaning process.

PDE, ADE and HBEL in Pharmaceutical Cleaning are often discussed together, but treating them as identical can create confusion in protocols, risk assessments and audit responses. A strong quality system defines the relationship clearly: HBEL describes the health-based framework, while PDE or ADE is the approved numerical exposure value used for the substance. Cleaning validation then translates that value into equipment and sample limits.

This article compares the terms, explains the toxicological basis, shows how the value flows into MACO and cleaning controls, and provides practical examples for shared pharmaceutical equipment.

Practical rule: use the current approved toxicological report as the source of truth. Do not copy a PDE, ADE or HBEL from an old spreadsheet, a different route, or an unrelated product without qualified review.

HBEL, PDE and ADE: the simple relationship

HBEL

The framework

Health-based exposure limit is the broad concept for a science-based exposure threshold.

PDE

A numerical value

Permitted daily exposure expresses an acceptable daily exposure, commonly in mg/day.

ADE

Another expression

Acceptable daily exposure is a related term used by some organizations and regulators.

Cleaning control

Practical application

The approved value supports MACO, surface limits, sample limits and shared-facility decisions.

In a controlled system, the terminology is less important than the scientific quality and traceability of the value. The report should define which term is used, its units, route, population, critical effect, derivation method, limitations and approval status.

Definitions and differences

Term	Definition	Common pharmaceutical use
Health-Based Exposure Limit (HBEL)	A science-based exposure threshold intended to protect people from adverse effects of a substance.	Umbrella framework for shared-facility risk identification and control.
Permitted Daily Exposure (PDE)	A permitted daily amount derived from pharmacological and toxicological data.	Often used as the previous product’s health-based input for MACO.
Acceptable Daily Exposure (ADE)	An acceptable daily amount unlikely to cause an adverse effect under defined conditions.	Common in US industry and toxicologically based carryover programs.
MACO	Maximum allowable carryover of a previous product into the next product.	Converts PDE/ADE into an equipment-specific residue mass.
NOAEL	No-observed-adverse-effect level from a relevant study.	May be a point of departure used when deriving PDE or ADE.
LOAEL	Lowest-observed-adverse-effect level.	May be used with expert justification when a NOAEL is unavailable.

EMA guidance uses health-based exposure limits for risk identification in shared facilities and describes PDE as a value derived from structured evaluation of pharmacological and toxicological evidence. The approved report should control the calculation, regardless of whether the site labels the value PDE, ADE or another HBEL term.

Why health-based limits changed cleaning validation

Older cleaning programs often relied on broad rules such as 10 ppm, one-thousandth of a therapeutic dose or “no visible residue.” These controls may still appear as supplementary criteria, but they do not describe the hazard of every substance. A highly potent compound, sensitizer or genotoxic impurity can require a much more protective approach.

Traditional control	Strength	Limitation
10 ppm	Simple to calculate and historically familiar.	Does not account for substance-specific toxicity or potency.
1/1000 of therapeutic dose	Includes some dose information.	May not reflect non-dose-related effects, sensitization or genotoxicity.
No visible residue	Important practical equipment-release control.	Cannot demonstrate absence of sub-visible chemical residue.
HBEL/PDE/ADE	Uses substance-specific health information.	Requires qualified toxicology, current data and careful implementation.

Health-based limits do not make traditional controls irrelevant. A cleaning protocol should combine the approved health-based residue limit with visual, microbiological, detergent, process-parameter and product-quality criteria.

How PDE and ADE are derived

PDE or ADE derivation starts with a critical review of available evidence. The qualified toxicologist selects a point of departure and applies appropriate uncertainty or adjustment factors. The result should be route-specific and should account for data quality, critical effects, sensitive populations and the intended exposure scenario.

Mechanism of action and pharmacological activity
Clinical dose, adverse effects and therapeutic index
Human pharmacokinetics and exposure
Repeat-dose and chronic toxicity
Genotoxicity and carcinogenicity
Reproductive and developmental toxicity

Local toxicity and sensitization
Metabolites, impurities and degradants
Route-specific absorption and bioavailability
Species differences and sensitive groups
Study limitations and data gaps
Regulatory or product-label information

Illustrative derivation relationship

PDE or ADE (mg/day) = [Point of departure (mg/kg/day) × reference body weight (kg)] ÷ [F1 × F2 × F3 × F4 × F5] The point of departure, body weight, factors and route adjustments must be selected and justified by a qualified toxicologist.

The formula is a teaching model, not a universal calculator. Different guidelines and substances may require different factors, route adjustments or approaches. The complete report—not an isolated formula—provides the defensible health-based value.

Illustrative PDE example

Assume a fictional active has a point of departure of 1.5 mg/kg/day, a 50 kg reference body weight and uncertainty factors F1 = 5, F2 = 10, F3 = 1, F4 = 1 and F5 = 1.

PDE = (1.5 mg/kg/day × 50 kg) ÷ (5 × 10 × 1 × 1 × 1) PDE = 75 mg/day ÷ 50 PDE = 1.5 mg/day

This fictional result may then be used as an input for shared-facility risk assessment and a product-pair MACO calculation. It is not a substitute for a toxicologist’s review of the substance’s full evidence package.

How PDE, ADE and HBEL feed into MACO

The approved numerical value becomes useful to Validation when it is converted into a carryover limit for a specific previous-product and next-product pair.

MACO (mg) = [PDE or ADE of previous product (mg/day) × minimum batch size of next product (mg)] ÷ maximum daily dose of next product (mg/day) Surface limit (µg/cm²) = [MACO (mg) × 1,000] ÷ total shared contact area (cm²) Swab limit (µg/swab) = surface limit (µg/cm²) × approved swab area (cm²)

The same PDE/ADE can produce different MACO values for different next products. A smaller next batch or a higher next-product daily dose generally creates a more restrictive result. For a detailed numerical MACO walkthrough, use the related Cleaning Validation in Pharmaceuticals resource.

Worked example: from PDE to surface limit

Assume the approved PDE for a previous product is 0.01 mg/day. The next product has a minimum batch size of 10 kg and a maximum daily dose of 500 mg/day. The shared equipment train has 200,000 cm² of product-contact area.

Input	Value	Use
Previous-product PDE	0.01 mg/day	Health-based input
Next-product minimum batch	10 kg = 10,000,000 mg	Convert before calculation
Next-product maximum daily dose	500 mg/day	Highest relevant intake
Shared product-contact area	200,000 cm²	Complete equipment train

MACO = (0.01 mg/day × 10,000,000 mg) ÷ 500 mg/day = 200 mg of previous-product residue Surface limit = (200 mg × 1,000 µg/mg) ÷ 200,000 cm² = 1 µg/cm²

If a 25 cm² swab is used, the recovery-corrected sample limit is 25 µg/swab. The laboratory method and recovery convention must support that final value before the protocol is approved.

Shared-facility decisions using HBEL

HBEL is not only a cleaning calculation. It supports a broader assessment of whether a facility, room, equipment train or personnel flow can safely support multiple products.

Decision area	Questions	Possible control
Equipment sharing	Can the cleaning process reliably achieve the HBEL-derived limit?	Validate cleaning, improve design, increase verification or dedicate equipment.
Room sharing	Can dust, aerosol, waste and personnel routes be controlled?	Containment, pressure cascade, HVAC control, cleaning and segregation.
Product hazard	Is the substance potent, sensitizing, genotoxic, cytotoxic or hormonal?	Enhanced containment, dedicated areas or specialist risk assessment.
Analytical capability	Can the laboratory measure below the health-based limit?	Method improvement, marker selection, alternative sampling or dedication.
Campaign length	Does extended production increase soil, residue or microbial risk?	Campaign limits, dirty hold-time assessment and additional verification.

A high HBEL does not automatically make every shared arrangement acceptable. Equipment must still be visually clean, suitable for its intended use and protected from microbial or detergent contamination.

Special cases: when terminology is not enough

Highly potent

Use containment

A restrictive ADE/PDE may support dedicated equipment, closed transfer or enhanced containment.

Sensitizer

Consider tiny exposures

Allergenic response may justify controls more protective than a conventional dose-based rule.

Biologic

Protect activity

Consider denaturation, immunogenicity, biological activity and protein-specific testing.

Microbial risk

Control growth

Use drying, hold-time, water-quality, bioburden and endotoxin controls where relevant.

For genotoxic compounds, reproductive hazards, allergens, hormones and cytotoxics, involve toxicology and Regulatory Affairs early. A numerical value should not be used to justify sharing when the process cannot reliably control the exposure pathway.

Cleaning-validation criteria beyond PDE and ADE

A complete cleaning-validation protocol should use health-based limits alongside practical and product-quality controls.

Criterion	Why it is needed	Typical evidence
Previous-product residue	Controls chemical carryover against the approved PDE/ADE-derived limit.	Specific swab, rinse or marker assay.
Visual cleanliness	Detects visible residue and supports equipment release.	Trained inspection under defined lighting and access.
Detergent residue	Prevents cleaning agents from affecting the next product.	Specific assay, conductivity, TOC or justified no-detectable-residue criterion.
Microbial and endotoxin	Controls contamination independent of chemical carryover.	Bioburden, objectionable organisms, endotoxin or hold-time studies.
Process parameters	Shows the cleaning cycle was executed as validated.	Time, temperature, flow, concentration, pressure and recipe records.

Analytical and sampling controls

Health-based limits often become very low for potent substances. The analytical method, sample recovery and sampling design must therefore be developed together.

LOQ below the final sample acceptance limit
Specificity for the active or justified marker
Recovery on relevant product-contact materials
Accuracy and precision near the limit
Stable sample and extraction solution

Worst-case direct-surface locations
Defined swab area or rinse volume
Raw versus recovery-corrected reporting
Blank, negative and positive controls
Below-LOQ and invalid-result rules

Direct surface sampling is important when feasible because a clean rinse may not represent a difficult-to-clean surface. Rinse sampling can supplement swabs for inaccessible paths when its representativeness is justified.

Governance: who owns the decision?

Toxicology owns derivation

Qualified experts select data, point of departure and adjustment factors.

Quality owns control

QA approves reports, revisions, applicability, deviations and change impact.

Validation owns translation

Validation converts PDE/ADE into MACO, surface and sample criteria.

Production owns execution

Operators follow the current cleaning method and record actual parameters.

QC owns measurement

The laboratory controls method performance, recovery, calculations and results.

Engineering supports design

Equipment area, materials, access, drainage and automation remain accurate.

Use the controlled SOP system to define responsibilities, review frequency, training, record retention and change control.

Data integrity and electronic records

PDE, ADE and HBEL decisions often move through toxicology reports, spreadsheets, laboratory systems, equipment databases and electronic quality systems. Apply ALCOA+ to source data, calculations, approvals, audit trails and version history.

Keep the original toxicological source and approved report revision.
Protect formulas, input cells and calculation worksheets from uncontrolled edits.
Record who entered, reviewed and approved the value and when.
Retain audit trails and evidence of changes to PDE, ADE, MACO or sampling limits.
Assess applicable 21 CFR electronic-record and signature controls.

A value that cannot be reconstructed from approved evidence should not be used as a critical GMP input.

Connection to equipment qualification

Health-based limits must be achievable on the equipment. Link shared-surface area, materials, access, drainage, containment and cleaning capability to the qualification lifecycle.

Requirements

URS

Captures cleanability, containment, materials and intended use.

Design

DQ

Confirms the design supports cross-contamination controls.

Installation

IQ

Verifies installed materials, components and utilities.

Operation

OQ

Challenges cleaning recipes, alarms, ranges and controls.

PQ and cleaning-validation studies then demonstrate that the qualified equipment and cleaning process can meet the health-based limits in actual operation.

Review, change control and CAPA

Review PDE, ADE and HBEL values when new safety information, impurities, routes, formulations, strengths or patient populations become available. Reassess the cleaning program when equipment, detergent, process parameters, analytical methods or product sequences change.

New toxicology, clinical or pharmacology data
New adverse event, safety signal or regulatory action
New active, impurity, metabolite or degradant
New shared-equipment request
HBEL-derived limit below method capability

Cleaning failure or adverse residue trend
Equipment design or surface-area change
Detergent or cleaning-parameter change
Sampling or analytical-method change
Periodic-review or regulatory update

Route systemic weaknesses through CAPA and use the established CAPA procedure for investigation, action ownership and effectiveness review.

Audit checklist for PDE, ADE and HBEL

Every shared-facility substance has an HBEL status or documented rationale.
PDE/ADE report identifies author, reviewer, date, revision and applicability.
Point of departure and uncertainty factors are explained.
Route, patient population and critical effect are documented.
MACO and residue limits trace to the approved health-based value.
Special hazards and dedication decisions are addressed.

Analytical LOQ and recovery support the final criteria.
Visual, microbial and detergent controls remain in place.
Equipment surface area and cleanability evidence are current.
Electronic records meet ALCOA+ and 21 CFR expectations.
Review and revalidation triggers are defined.
Deviations and actions are linked to CAPA and change control.

Frequently asked questions

What is the difference between HBEL, PDE and ADE?

HBEL is the broad health-based exposure-limit concept. PDE and ADE are commonly used numerical expressions of an acceptable daily exposure to a substance.

Which value is used for cleaning validation?

The current approved PDE or ADE, or another approved HBEL expression, is used as the health-based input for carryover and cleaning-validation decisions.

Who should derive PDE or ADE?

A qualified toxicologist or appropriately trained subject-matter expert should lead the derivation and document the scientific rationale.

Does HBEL replace the 10 ppm rule?

HBEL provides a more substance-specific basis where available. A legacy 10 ppm value may remain a supplementary criterion but should not override a more protective health-based limit.

How does PDE affect MACO?

PDE or ADE is combined with the next product’s minimum batch size and maximum daily dose to calculate the maximum allowable carryover mass.

Does a high PDE mean no cleaning validation is needed?

No. Cleaning, visual inspection, microbial controls, detergent controls and equipment-release requirements remain necessary.

What if the PDE-derived limit is below the analytical LOQ?

Do not increase the limit to match the LOQ. Improve the method, revise sampling, use a justified marker, redesign equipment or assess dedication.

When should an HBEL report be updated?

Update or review it after new safety data, adverse signals, new impurities, route or formulation changes, new products, equipment changes, cleaning failures or regulatory updates.

Can PDE and ADE be used for biologics?

They may inform the assessment, but biologics may require additional considerations such as biological activity, immunogenicity, denaturation and protein-specific methods.

How should PDE, ADE and HBEL records be controlled?

Use qualified review, revision control, ALCOA+ data-integrity safeguards, validated electronic systems and traceable links to MACO, protocols, deviations and CAPA.

Conclusion

PDE, ADE and HBEL in Pharmaceutical Cleaning describe the health-based foundation for controlling carryover in shared facilities. HBEL is the framework; PDE or ADE is the approved numerical exposure value; MACO and cleaning-validation limits are the practical manufacturing applications.

A defensible program combines qualified toxicology with current product data, equipment knowledge, validated cleaning, measurable analytical methods, visual and microbial controls, data integrity and lifecycle review. Integrate the decision into your cGMP system and controlled procedures so that the value remains scientifically current and operationally achievable.